1. Abid Hussein M.N., Meesters E.W., Osmanovic N., Romijn F.P.,Nieuwland R., Sturk A.: Antigenic characterization of endothelialcell-derived microparticles and their detection ex vivo. J. Thromb.Haemost., 2003; 1: 2434–2443
2. Andreasen P.A., Egelund R., Petersen H.H.: The plasminogen activationsystem in tumor growth, invasion, and metastasis. Cell. Mol.Live Sci., 2000; 57: 25–40
3. Bansal V., Roychoudhury P.: Production and purification of urokinase:a comprehensive review. Protein Expr. Purif., 2006; 45: 1–14
4. Banys-Paluchowski M., Witzel I., Aktas B., Fasching P.A., HartkopfA., Janni W., Kasimir-Bauer S., Pantel K., Schön G., Rack B., RiethdorfS., Solomayer E.F., Fehm T., Müller V.: The prognostic relevance ofurokinase-type plasminogen activator (uPA) in the blood of patientswith metastatic breast cancer. Sci. Rep., 2019; 9: 2318 5 Behzadian M.A., Windsor L.J., Ghaly N., Liou G., Tsai N.T., CaldwellR.B.: VEGF-induced paracellular permeability in cultured endothelialcells involves urokinase and its receptor. FASEB J., 2003; 17: 752–754
5. Behzadian M.A., Windsor L.J., Ghaly N., Liou G., Tsai N.T., Caldwell R.B.: VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J., 2003; 17: 752–754